What is CJC-1295 (no DAC)?

CJC-1295 without DAC is the common wellness-market name for Modified GRF 1-29, a modified version of the active 1-29 region of growth-hormone-releasing hormone. The practical identity point is simple: it is a GHRH analog, not growth hormone itself. [1][2]

The no-DAC distinction matters because the molecule does not carry the albumin-binding tail. CJC-1295 was engineered to stay in circulation much longer through albumin binding; no-DAC Modified GRF 1-29 is discussed as the shorter-acting, pulse-oriented member of the same GHRH-analog family. [7][8][18]

The biological idea is upstream signaling. GHRH fragments and D-Ala2 analogs can stimulate pituitary GH release in normal men, and older GHRH(1-29) studies show GH and IGF-1 movement after repeated subcutaneous dosing. [1][3][2]

The naming needs precision. CJC-1295, CJC-1295 without DAC, sermorelin, tesamorelin, and CJC-1295 plus ipamorelin blends are related GH-axis topics, but they do not share the same duration, dosing logic, evidence package, or safety review. [18][7][5]

What CJC-1295 (no DAC) is investigated for

CJC-1295 (no DAC) evidence is grouped by practical use case and injectable route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

GH pulse and IGF-1 biomarker support

Injectable

50% Emerging

This is the strongest no-DAC claim: short-acting GHRH-fragment evidence supports GH-axis signaling, while direct no-DAC outcome evidence remains limited. [1][2][3]

Human evidence

Human GHRH(1-29) and D-Ala2 analog studies show pituitary GH response, lower metabolic clearance for the D-Ala2 analog, and repeated-dose GH/IGF-1 movement in older men. That supports the short-acting GHRH-fragment rationale but is not a dedicated no-DAC CJC-1295 clinical program. [1][2][3]

Animal / mechanistic evidence

The CJC-1295 comparator literature shows how albumin binding creates a different long-acting exposure profile. That contrast is the main mechanistic reason to separate no-DAC Modified GRF 1-29 from albumin-binding CJC-1295. [7][8]

Lean-mass and fat-loss outcomes

Injectable

45% Preliminary

Lean-mass and fat-loss improvement is commonly discussed for no-DAC CJC-1295, but it should read as an indirect GH-axis hypothesis rather than a proven result. [4][14]

Human evidence

Older human GHRH(1-29) studies measured GH/IGF-1, strength, DEXA, and metabolic variables, but they do not establish no-DAC CJC-1295 as a lean-mass or fat-loss treatment. Direct no-DAC fat-loss, lean-mass, or waist-outcome trials are missing. [3][4]

Animal / mechanistic evidence

The rationale comes from GH/IGF-1 biology and GHRH-axis signaling, not from no-DAC animal models showing lean-mass or fat-loss improvements in healthy adults. [7][10]

Sleep quality

Injectable

18% Insufficient

Sleep quality is a common no-DAC CJC-1295 tracking claim, but the evidence supports GH-axis timing physiology more than sleep endpoints. [4]

Human evidence

Nightly GHRH(1-29) studies measured nocturnal GH physiology, and bedtime timing is common in GH-oriented schedules. Those studies do not prove no-DAC CJC-1295 improves sleep quality, sleep stages, or insomnia symptoms. [4][3]

Animal / mechanistic evidence

The mechanism is timing and GH physiology rather than a direct sleep pathway. Evidence should not turn overnight GH rhythm into a sleep-quality claim without sleep endpoints. [9]

Recovery support

Injectable

16% Insufficient

Recovery support is commonly discussed with no-DAC CJC-1295, but it should be shown as an indirect GH-axis claim until recovery-specific human evidence exists. [14][15]

Human evidence

Controlled no-DAC CJC-1295 human evidence does not show faster exercise recovery, injury recovery, soreness reduction, strength gain, or training adaptation. Sports-medicine reviews keep unapproved peptide performance claims separate from proven outcomes. [14][15][16]

Animal / mechanistic evidence

Mechanistic support is limited to GH-axis plausibility and GHRH analog pharmacology. It does not replace recovery-specific human endpoints. [1][2]

Evidence snapshot

Overall confidence

Emerging

60%

No-DAC CJC-1295 has a plausible GH-axis rationale and adjacent human GHRH evidence, but less direct evidence than CJC-1295. The cleanest conclusion is pulse-oriented GH-axis signaling with weak direct proof for body-composition, sleep, or recovery outcomes. [1][2][3][8]

Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.

50%

Human evidence

Emerging

Human evidence supports GHRH(1-29) and D-Ala2 analog GH signaling, plus older repeated-dose GHRH(1-29) biomarker movement. Dedicated no-DAC CJC-1295 outcome trials are not established. [1][2][3]

40%

Animal / preclinical

Limited

Preclinical and analytical support mainly clarifies the GHRH-analog family and the DAC distinction. The no-DAC page should not borrow DAC mouse or rat outcomes as human no-DAC benefits. [7][13][12]

60%

Mechanism support

Moderate

Mechanism support is stronger than outcome support: no-DAC Modified GRF 1-29 is a GHRH-fragment analog, D-Ala2 modification reduces clearance, and the lack of DAC separates it from albumin-binding CJC-1295. [1][2][7]

Forms & administration

CJC-1295 no DAC is primarily discussed as a subcutaneous, short-acting GHRH analog. Route, DAC status, timing, product identity, and whether it is paired with a GHRP change how the schedule should be interpreted. [3][2]

Injectable

Dosing & protocols

The notes below separate published trial design from commonly discussed cosmetic or compounded-use patterns. They are educational context only, not a prescription or product instruction.

Typical Range

Common Modified GRF 1-29 protocols usually use 100-200 mcg per dose.

Frequency

Common no-DAC schedules usually use 1-3 doses daily because the no-DAC form is short acting and is used to create discrete GH-axis pulses. [2]

Timing Considerations

Morning, post-workout, and before-bed timing are the common anchors. Before-bed timing is used to align the signal with overnight GH physiology, while morning or training-day timing is used for schedule consistency. [4]

Cycle Length

Common no-DAC cycles usually run 8-12 weeks before reassessment.

Protocol Notes

CJC-1295 and no-DAC schedules are different. CJC-1295 is built for long duration through albumin binding; no-DAC Modified GRF 1-29 is organized around repeated short pulses. [7][8][18]

What to expect

Same day

Upstream GH-axis pulse, with practical notes around appetite, sleep timing, warmth or flushing, and recovery feel against normal baseline. [1][2][17]

First 1-2 weeks

Early GH and IGF-1 biomarker movement in responsive older men, alongside sleep quality, recovery feel, appetite, water retention, and day-to-day training tolerance. [3]

Weeks 4-8

Steadier lab movement, sleep and recovery patterns, body-composition trend, training tolerance, and metabolic measures across the protocol block. [4]

After stopping

Quick fade of the short-acting GH pulse, with slower settling of IGF-1 labs, weight trend, sleep, and training markers. [2][8]

Safety profile

CJC-1295 no DAC should be treated as endocrine-active and route-specific. Human GHRH-fragment studies are small or adjacent, while FDA flags CJC-1295 compounding concerns involving immunogenicity, peptide impurities, API characterization, increased heart rate, systemic vasodilatory reaction, and limited clinical data. [1][17][18]

Common side effects

Injection-site pain or swelling [18]
Flushing or warmth [1][17]
Headache [18]
Dizziness [17]
Low blood pressure [17]
Faster heart rate [17]

Cautions

Endocrine medical supervision [3]
Unapproved product quality [17][18]
Prohibited in sport [20]

What we don't know

Decision-changing unknowns include long-term safety, no-DAC versus DAC risk differences, combination-level safety with GHRPs, repeated non-study use, product identity, special-population safety, and whether downstream outcomes justify endocrine exposure. [17][18][14]

Who CJC-1295 (no DAC) is not for

Route-specific avoid and medical-review notes:

Competitive athletes
Competitive athletes should avoid CJC-1295 no DAC unless their anti-doping authority provides route-specific written clearance. WADA prohibits GHRH and analogs including CJC-1295. [20]
Endocrine disease or glucose dysregulation
Medical review is needed in endocrine disease, diabetes, insulin resistance, or abnormal GH/IGF-1-related labs because no-DAC CJC-1295 acts through the GH/IGF-1 axis. [3]
Cancer or growth-factor-sensitive conditions
This is a medical-review caution rather than a documented no-DAC cancer-outcome finding. GH/IGF-1 biomarker movement should not be handled through self-directed use in growth-factor-sensitive histories. [3][17]
Pregnancy, breastfeeding, or pediatric use
Pregnancy, breastfeeding, and pediatric use are not supported by route-specific no-DAC CJC-1295 safety data. [17][18]

Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

Theoretical interactions

Other GH-axis drugs or secretagogues
This is a theoretical additive-exposure caution. Combining no-DAC CJC-1295 with GH, GHRPs, ipamorelin, CJC-1295, sermorelin, tesamorelin, or other GH-axis agents can make GH/IGF-1 exposure and side-effect interpretation harder to manage. [3][17]
Glucose-active medications
This is a theoretical endocrine-monitoring caution. GH/IGF-1 signaling intersects with metabolic regulation, so insulin, diabetes drugs, or weight-management medications need clinician review. [3]

Pairing notes

Commonly included in these stacks

CJC-1295 no DAC / Ipamorelin

CJC-1295 no DAC / Ipamorelin is a short-pulse GH-axis stack. It combines a short-acting GHRH-side analog with Ipamorelin's ghrelin/GHS-receptor signal to organize discrete GH-release windows.

CJC-1295 (no DAC)Ipamorelin

Related peptides

CJC-1295

Regulatory status

United States

United States: not FDA-approved for human use as a drug. No approved CJC-1295 or Modified GRF 1-29 drug product was identified in the reviewed openFDA query, and FDA CJC-1295-related compounding materials distinguish DAC and non-DAC forms. [19][18][17]

Route	FDA drug approval	503A compounding
Injectable	Not Approved No approved CJC-1295 or Modified GRF 1-29 drug product was identified in the reviewed openFDA Drugs@FDA query. [19]	Flagged FDA lists CJC-1295 among nominated-but-withdrawn bulk substances with potential safety risks, and the PCAC review distinguishes CJC-1295-related substances including DAC and non-DAC forms. [17][18]

Injectable

FDA drug approval

Not Approved

No approved CJC-1295 or Modified GRF 1-29 drug product was identified in the reviewed openFDA Drugs@FDA query. [19]

503A compounding

Flagged

FDA lists CJC-1295 among nominated-but-withdrawn bulk substances with potential safety risks, and the PCAC review distinguishes CJC-1295-related substances including DAC and non-DAC forms. [17][18]

International

International status is route-, product-, and claim-specific. No country-specific therapeutic approval outside the United States is established in this review.

Sports & competition

Sports competition: prohibited under WADA S2 growth hormone releasing factors. The prohibition covers GHRH and analogs including CJC-1295, regardless of no-DAC labeling. [20]

How it works

The starting point is natural GHRH. The active 1-29 region can stimulate pituitary somatotroph cells to release GH, and human bolus data show both native GHRH(1-29)-NH2 and a D-Ala2 analog can produce GH responses. [1]

The D-Ala2 modification helps explain why Modified GRF 1-29 exists as a research-market concept. In normal men, D-Ala2 GHRH(1-29) showed lower metabolic clearance and a longer disappearance half-time than native GHRH(1-29)-NH2. [2]

The no-DAC form lacks the albumin-binding extension that defines CJC-1295. The long-acting form was designed around albumin binding and multi-day exposure, so it should not be used as a drop-in schedule model for no-DAC Modified GRF 1-29. [7][8][18]

The translation limit is downstream outcomes. A GH pulse and IGF-1 movement can be biologically meaningful, but they do not automatically prove better sleep, faster recovery, fat loss, muscle gain, cognition, or vitality. [4][5][14]

Research gaps & open questions

What the current literature has not yet settled about CJC-1295 (no DAC):

Dedicated no-DAC CJC-1295 human trials are the largest evidence gap. Most human support comes from GHRH(1-29), D-Ala2 analog, tesamorelin, or albumin-binding CJC-1295 sources that must be labeled as adjacent. [2][3][8]

Direct outcome trials are missing for body composition, sleep quality, recovery, training adaptation, and vitality claims. [14][15]

No-DAC versus DAC head-to-head safety and efficacy have not been settled, including whether pulse-oriented schedules produce meaningfully different long-term risk or benefit. [8][18]

Combination-level evidence is needed for no-DAC CJC-1295 plus ipamorelin or other GHRPs, especially dosing, monitoring, side effects, and anti-doping status. [20]

Common questions

What is the difference between CJC-1295 and no DAC?

CJC-1295 has an albumin-binding extension designed for long duration. No-DAC CJC-1295 is usually Modified GRF 1-29, a shorter-acting GHRH analog used around pulse timing rather than multi-day exposure. [7][8][18]

What is CJC-1295 no DAC investigated for?

It is mainly discussed for GH pulse and IGF-1 biomarker support, body-composition improvements, sleep quality, and recovery support. The strongest support is GH-axis signaling; the downstream results remain weak. [1][3][4]

What is the CJC-1295 no DAC dose?

Common Modified GRF 1-29 protocols usually use 100-200 mcg per dose, 1-3 times daily, with morning, post-workout, or before-bed timing.

Can CJC-1295 no DAC be combined with ipamorelin?

No-DAC CJC-1295 and ipamorelin are a common GH-axis stack candidate because they act through different signaling pathways. Combination-level efficacy, safety, dosing, monitoring, and sports status still need separate review before the pair is treated as recommended. [14][20]

Is CJC-1295 no DAC allowed in sport?

No for WADA-governed sport. WADA prohibits growth hormone releasing factors, including GHRH analogs such as CJC-1295, at all times. [20][12]

Myths & misconceptions

Myth

No-DAC CJC-1295 is just faster CJC-1295.

Reality

They should be treated as different pharmacology problems. DAC adds albumin-binding chemistry and multi-day exposure; no-DAC Modified GRF 1-29 lacks that extension and is scheduled around short pulses. [7][8][18]

Myth

Pulse-oriented dosing proves no-DAC is safer.

Reality

Shorter exposure may change the risk profile, but it does not prove long-term safety. Both forms act through GH/IGF-1 biology, and CJC-1295-related products still carry product-quality and endocrine-monitoring concerns. [17][3]

Myth

CJC-1295 no DAC plus ipamorelin is a proven recovery stack.

Reality

The pair is common and mechanistically coherent, but combination-level outcome, safety, dose, timing, and anti-doping evidence need their own review. [14][20]

History & discovery

No-DAC CJC-1295 sits at the intersection of older GHRH(1-29) pharmacology, D-Ala2 analog work, and later CJC-1295 development. Its public use pattern grew from a naming shortcut for Modified GRF 1-29, not from a dedicated no-DAC approval program. [1][2][7][18]

A human study found GHRH(1-29)-NH2 and a D-Ala2 analog stimulated GH release in normal men, with the D-Ala2 analog showing greater potency. [1]

Older-men studies examined repeated GHRH(1-29) dosing, while a D-Ala2 GHRH(1-29) pharmacokinetic study found lower clearance than native GHRH(1-29). [3][2]

CJC-1295 was identified as a long-lasting albumin-binding GHRH analog and then studied in healthy adults for multi-day GH and IGF-1 biomarker response. [7][8]

Analytical and sports-medicine literature discusses modified GRF and GHRH analogs in doping and unapproved peptide settings, while FDA materials continue to distinguish CJC-1295-related forms for compounding review. [11][12][18]

Published research 20 studies

[1]

Growth hormone responses to growth hormone-releasing hormone (1-29)-NH2 and a D-Ala2 analog in normal men.

PubMed / Peptides, 1985. human clinical.

[2]

Incorporation of D-Ala2 in growth hormone-releasing hormone-(1-29)-NH2 increases the half-life and decreases metabolic clearance in normal men.

PubMed / Journal of Clinical Endocrinology and Metabolism, 1994. human clinical.

[3]

Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men.

PubMed / Journal of Clinical Endocrinology and Metabolism, 1992. human clinical.

[4]

Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men.

PubMed / Metabolism, 1997. human clinical.

[5]

Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial.

PubMed Central / Archives of Neurology, 2012. human clinical.

[6]

Growth hormone releasing hormone improves the cognition of healthy older adults.

PubMed / Neurobiology of Aging, 2006. human clinical.

[7]

Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog.

PubMed / Endocrinology, 2005. animal.

[8]

Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.

PubMed / Journal of Clinical Endocrinology and Metabolism, 2006. human clinical.

[9]

Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.

PubMed / Journal of Clinical Endocrinology and Metabolism, 2006. human clinical.

[10]

Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects.

PubMed Central / Growth Hormone & IGF Research, 2009. human clinical.

[11]

Glycine-modified growth hormone secretagogues identified in seized doping material.

PubMed / Drug Testing and Analysis, 2019. regulatory.

[12]

Advances in the detection of growth hormone releasing hormone synthetic analogs.

PubMed / Drug Testing and Analysis, 2021. ex vivo.

[13]

An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma.

PubMed / Drug Testing and Analysis, 2019. ex vivo.

[14]

Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.

PubMed / Sports Medicine, 2026. review.

[15]

Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications.

PubMed / JBJS Reviews, 2026. review.

[16]

Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.

PubMed / American Journal of Sports Medicine, 2026. review.

[17]

Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks

U.S. Food and Drug Administration. regulatory.

[18]

FDA Evaluation of CJC-1295 Related Bulk Drug Substances for the December 4, 2024 Pharmacy Compounding Advisory Committee Meeting

U.S. Food and Drug Administration, 2024. regulatory.

[19]

openFDA Drugs@FDA query for CJC-1295 no-DAC and Modified GRF 1-29

openFDA / U.S. Food and Drug Administration. database query.

[20]

2026 Prohibited List: International Standard

World Anti-Doping Agency, 2025. official guidance.